Truist lowered the firm’s price target on Zimmer Biomet to $130 from $137 and keeps a Hold rating on the shares after its Q1 results. The company has called out a few key drivers in Hips and Knee businesses that should contribute to acceleration into the second half of the year, though its guidance saw “minimal” flow-through from the modest Q1 revenue and earnings beat, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH:
- Zimmer Biomet backs FY24 adjusted EPS view $8.00-$8.15, consensus $8.06
- Zimmer Biomet reports Q1 adjusted EPS $1.94, consensus $1.87
- Zimmer Biomet Announces First Quarter 2024 Financial Results
- Notable companies reporting before tomorrow’s open
- Zimmer Biomet becomes official medical device partner of U.S. pickleball